← FDA DRUG APPROVALS

FDA NDA · NDA220089

PIFLUFOLASTAT F-18

Sponsor: APHELION

APPLICATION
NDA220089
TYPE
NDA
ORIGINAL APPROVAL
2026-03-06
LATEST ACTION
2026-03-06
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

PYLARIFY TRUVU · ReferencePrescription
PIFLUFOLASTAT F-18 1mCi/mL-120mCi/mL · SOLUTION · INTRAVENOUS

Approval history

2026-03-06Type 5 - New Formulation or New Manufacturer · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →